Ardelyx Inc
ARDX4.330USD
0.0000.00%
收盤 08/01, 16:00（美東）報價延遲15分鐘
1.04B總市值
虧損本益比TTM
關於 Ardelyx Inc 公司
Ardelyx, Inc. 是一家生物製藥公司。該公司專注於發現、開發和商業化滿足重大未滿足醫療需求的先進藥物。它有兩種商業產品 IBSRELA（tenapanor）和 XPHOZAH。其產品線包括 RDX013 計劃和 RDX020 計劃。Tenapanor 是一種正在開發的小分子療法，用於治療或控制透析成年慢性腎病 (CKD) 患者的高磷血癥或血清磷。Tenapanor 具有作用機制，在腸道局部作用以抑制鈉氫交換器 3 (NHE3)。IBSRELA 是爲治療便祕型腸易激綜合徵 (IBS-C) 患者而開發的。XPHOZAH 是一種用於控制透析成年 CKD 患者血清磷的藥物。RDX013 計劃是一種用於治療高鉀血癥的小分子鉀促泌劑計劃。 RDX020 計劃是一種用於治療代謝性酸中毒的小分子。
公司簡介
公司代碼ARDX
公司名稱Ardelyx Inc
上市日期Jun 19, 2014
CEOMr. Michael G. (Mike) Raab
員工數量395
證券類型Ordinary Share
年結日Jun 19
公司地址400 Fifth Avenue
城市WALTHAM
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02451
電話15107451700
網址https://www.ardelyx.com/
公司代碼ARDX
上市日期Jun 19, 2014
CEOMr. Michael G. (Mike) Raab
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
2.86M
+19.80%
Mr. Michael G. (Mike) Raab
Mr. Michael G. (Mike) Raab
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
477.14K
-12.42%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
413.54K
+17.98%
Mr. Eric Foster
Mr. Eric Foster
Chief Commercial Officer
Chief Commercial Officer
314.17K
-0.79%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
137.35K
+43.37%
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Independent Director
Independent Director
41.55K
--
James Brady
James Brady
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. Merdad Parsey, M.D., Ph.D.
Dr. Merdad Parsey, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Mike Kelliher
Mr. Mike Kelliher
Chief Business Officer
Chief Business Officer
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
2.86M
+19.80%
Mr. Michael G. (Mike) Raab
Mr. Michael G. (Mike) Raab
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
477.14K
-12.42%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
413.54K
+17.98%
Mr. Eric Foster
Mr. Eric Foster
Chief Commercial Officer
Chief Commercial Officer
314.17K
-0.79%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
137.35K
+43.37%
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Independent Director
Independent Director
41.55K
--
收入明細
FY2025Q1
FY2024
FY2024Q2
FY2024Q1
業務USD
名稱
營收
佔比
IBSRELA
44.40M
0.00%
XPHOZAH
23.41M
0.00%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
IBSRELA
44.40M
0.00%
XPHOZAH
23.41M
0.00%
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Janus Henderson Investors
10.44%
The Vanguard Group, Inc.
6.70%
BlackRock Institutional Trust Company, N.A.
6.64%
Millennium Management LLC
5.06%
Macquarie Investment Management
4.66%
Other
66.50%
持股股東
持股股東
佔比
Janus Henderson Investors
10.44%
The Vanguard Group, Inc.
6.70%
BlackRock Institutional Trust Company, N.A.
6.64%
Millennium Management LLC
5.06%
Macquarie Investment Management
4.66%
Other
66.50%
股東類型
持股股東
佔比
Investment Advisor
27.48%
Investment Advisor/Hedge Fund
26.34%
Hedge Fund
13.49%
Research Firm
4.93%
Individual Investor
2.66%
Bank and Trust
0.37%
Pension Fund
0.36%
Family Office
0.09%
Insurance Company
0.03%
Other
24.24%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
460
181.09M
75.69%
+6.96M
2025Q1
470
173.66M
72.61%
+2.64M
2024Q4
452
158.29M
66.42%
-9.57M
2024Q3
441
149.04M
63.31%
-41.81M
2024Q2
420
152.02M
64.97%
-36.87M
2024Q1
399
149.36M
64.27%
-40.02M
2023Q4
363
143.31M
61.82%
-29.22M
2023Q3
347
131.10M
60.21%
-55.04M
2023Q2
355
129.77M
60.57%
-68.74M
2023Q1
359
119.15M
57.99%
-45.93M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Janus Henderson Investors
24.98M
10.44%
+589.07K
+2.42%
Mar 31, 2025
The Vanguard Group, Inc.
14.94M
6.25%
+634.58K
+4.44%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
15.88M
6.64%
-651.24K
-3.94%
Mar 31, 2025
Millennium Management LLC
12.10M
5.06%
+5.63M
+87.15%
Jun 17, 2025
Macquarie Investment Management
11.16M
4.66%
+811.55K
+7.84%
Mar 31, 2025
State Street Global Advisors (US)
10.18M
4.25%
-1.42M
-12.22%
Mar 31, 2025
Marshall Wace LLP
8.38M
3.5%
+8.27M
+7201.76%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.67M
2.37%
+162.88K
+2.96%
Mar 31, 2025
Nuveen LLC
3.39M
1.42%
+1.24M
+57.47%
Mar 31, 2025
Citadel Advisors LLC
3.19M
1.33%
+699.74K
+28.09%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Products ETF
2.03%
Harbor Human Capital Factor US Small Cap ETF
0.53%
Invesco NASDAQ Future Gen 200 ETF
0.48%
SPDR S&P Biotech ETF
0.36%
Direxion Daily S&P Biotech Bull 3X Shares
0.2%
First Trust Small Cap Growth AlphaDEX Fund
0.18%
Inspire Small/Mid Cap ESG ETF
0.16%
Invesco Nasdaq Biotechnology ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
iShares Russell 2000 Growth ETF
0.06%
查看更多
Virtus LifeSci Biotech Products ETF
佔比2.03%
Harbor Human Capital Factor US Small Cap ETF
佔比0.53%
Invesco NASDAQ Future Gen 200 ETF
佔比0.48%
SPDR S&P Biotech ETF
佔比0.36%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.2%
First Trust Small Cap Growth AlphaDEX Fund
佔比0.18%
Inspire Small/Mid Cap ESG ETF
佔比0.16%
Invesco Nasdaq Biotechnology ETF
佔比0.1%
ProShares Ultra Nasdaq Biotechnology
佔比0.1%
iShares Russell 2000 Growth ETF
佔比0.06%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
